IMGN - AbbVie's New $9B Neuroscience Space Deal Might Attract FTC Scrutiny Analyst Signals | Benzinga
Wednesday, AbbVie Inc (NYSE: ABBV) agreed to acquire Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) for a total equity value of approximately $8.7 billion, or $45 per share in cash, with the transaction anticipated to close in the middle of 2024.
The deal comes just a couple of days after AbbVie agreed to acquire ImmunoGen Inc (NASDAQ: IMGN) for $31.26 per share in cash, equivalent to a total equity value of approximately $10.1 billion.
William Blair highlights AbbVie's clear interest in expanding its ...